Extended Data Fig. 8: Detection of neutralizing antibodies in clinical samples.
a, Serum from convalescent and/or vaccinated patients (positive samples, n=40) and pre-2019 samples (negative samples, n=24) were collected and tested in both the lucCageRBD and ELISA assay and pseudovirus infection against WT RBD. b, The same samples were tested for neutralization of either WT or Delta spike-presenting pseudovirus with log10 IC50 neutralization reported. Viral infection experiments were performed in duplicate, and data are mean ± s.e.m. r represents pearson’s coefficient. **P=0.0012, two-tailed student’s t-test.
